Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

• Published in: Annals of the rheumatic diseases Vol. 82; no. 4; pp. 575 - 577
• Main Authors: Dougados, Maxime, Charles-Schoeman, Christina, Szekanecz, Zoltán, Giles, Jon T, Ytterberg, Steven R, Bhatt, Deepak L, Koch, Gary G, Vranic, Ivana, Wu, Joseph, Wang, Cunshan, Kwok, Kenneth, Menon, Sujatha, Connell, Carol A, Yndestad, Arne, Rivas, Jose L, Buch, Maya H
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and European League Against Rheumatism 01.04.2023; Elsevier Limited; BMJ Publishing Group
• Subjects: Antirheumatic Agents; Antirheumatic Agents - adverse effects; Arthritis, Rheumatoid; Arthritis, Rheumatoid - chemically induced; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; Cardiology; Cardiovascular disease; Cardiovascular Diseases; Cardiovascular Diseases - chemically induced; Clinical trials; Coronary vessels; Heart Disease Risk Factors; Humans; Incidence; Letter; Patients; Pyrroles - adverse effects; Rheumatoid arthritis; Risk Factors; Surveillance; Treatment Outcome; Vein & artery diseases; New York; United States > US; Antirheumatic Agents; Cardiovascular Diseases; Arthritis, Rheumatoid